MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery. The target population of this study are ovarian cancer patients who experience a disease recurrence or progression to a first line maintenance therapy with PARPi; at progression patients must have received a secondary cytoreduction according to clinical practice.

Trial Details

NCT ID
NCT05255471
Phase
PHASE3
Sponsor
National Cancer Institute, Naples
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Olaparib
  • Chemotherapy drug
Locations (sample)
  • Naples, Italy|40.85216,14.26811

Key Eligibility Criteria

  • Signed informed consent prior to any study specific procedures;
  • Female, age ≥ 18 years at time of signing informed consent
  • Patients with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer recurrent or progressive after first line PARP…
  • Patients must have received only one previous line of a platinum containing regimen not containing bevacizumab;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →